Advertisement
Screener

KURA ONCOLOGY, INC. (KURA) Deferred Tax Assets, Net of Valuation Allowance

2.8 / 5 stars · 68/120 Roast Me

KURA ONCOLOGY, INC. Deferred Tax Assets, Net of Valuation Allowance

KURA ONCOLOGY, INC. (KURA) had Deferred Tax Assets, Net of Valuation Allowance of $1.34 million as of 2022-12-31, per its 10-K filed 2023-02-23.

Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance

us-gaap:DeferredTaxAssetsNet · last filed 2023-02-23

  • 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $1.34M.
  • 2021-12-31: Deferred Tax Assets, Net of Valuation Allowance $1.87M.
  • 2020-12-31: Deferred Tax Assets, Net of Valuation Allowance $2.12M.
  • 2019-12-31: Deferred Tax Assets, Net of Valuation Allowance $165.00K; Deferred Tax Assets, Net of Valuation Allowance as first filed $0.00.
Period endDeferred Tax Assets, Net of Valuation AllowanceDeferred Tax Assets, Net of Valuation Allowance as first filed
2022-12-31$1.34M
10-K · filed 2023-02-23
2021-12-31$1.87M
10-K · filed 2023-02-23
2020-12-31$2.12M
10-K · filed 2022-02-24
2019-12-31$165.00K
10-K · filed 2021-02-24
$0.00
10-K · filed 2020-02-25
2018-12-31$0.00
10-K · filed 2020-02-25
2017-12-31$0.00
10-K · filed 2019-03-05
2016-12-31$0.00
10-K · filed 2018-03-12
2015-12-31$0.00
10-K · filed 2017-03-14
2014-12-31$0.00
10-K · filed 2016-03-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Apnimed, Inc. (APMD)United States$0.899B
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Savara Inc (SVRA)United States$1.044B-9.10
Theravance Biopharma, Inc. (TBPH)$0.885B16.40